Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleClinical improvement and reduction of immunosuppressive drug therapy in cannabis treated patients with crohn's disease.
Author(s)Hergenrather JY, Mikuriya TH, Bearman D.
Journal, Volume, IssueIACM 3rd Conference on Cannabinoids in Medicine, 9-10 September 2005, Leiden, International Association for Cannabis as Medicine.
Major outcome(s)The majority of patients found a substantial improvement of their symptoms

California physicians involved in the practice of cannabis consultations regularly encounter patients with autoimmune and idiopathic inflammatory conditions. Patients with Crohn's disease occupy a proportionate number of these cases. The Crohn's patients encountered by these physicians have been treated with a variety of conventional pharmacological therapies including steroids, other immunomodulators and a number of biologic therapies, including anti tumor necrosis factor. Some have already had severe anorectal complications such as obstruction, fistula and abscess formation resulting in surgical intervention. The authors interviewed and examined patients seeking a physician statement of recommendation as required by California law. The vast majority of these cases are non-naïve cannabis patients, i.e. they have found that the use of cannabis is associated with clinical improvement prior to seeking physician approval.
The primary aim of this pilot study is to evaluate the efficacy of the ad lib use of natural cannabis in alleviating the symptoms of active Crohn's disease both with and without concomitant use of steroids and other immunomodulators. A secondary aim of the study is to determine if cannabis in combination with steroids and other immunomodulators leads to better response, longer periods of disease quiescence, and reduction in the use of steroids and other immunomodulator pharmaceuticals.
We performed a retrospective chart review of 20 patients with Crohn's disease who were approved to use cannabis for relief of symptoms, including abdominal pain, diarrhea, fatigue, anorexia and weight loss as principal complaints. All patients studied had an independent diagnosis of Crohn's disease from their primary or specialist physicians. Inclusion criteria also included the completion of a follow-up questionnaire designed to elicit details of the clinical course and use of all medications including cannabis. Data were collected on patient demographics, clinical response to cannabis, prednisone dose, concomitant immunomodulator therapy, complications and adverse effects.
Preliminary results indicate that the majority of patients found a substantial improvement of their clinical course and a marked reduction or discontinuation of conventional pharmaceutical therapy following the regular use of cannabis. Co-therapies included azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX), Infliximab (anti-TNF alpha), prednisone, mesalamine, and antibiotics. Cannabis purportedly serves as an effective immunomodulator, antispasmodic and appetite stimulant with a wide margin of safety and freedom of undesirable adverse effects compared with conventional pharmacotherapy.

Duration (days)
Participants20 patients with Crohn's disease
Type of publicationMeeting abstract
Address of author(s)Society of Cannabis Clinicians / California Cannabis Research Medical Group PO Box 9143 Berkeley, CA 94709 USA
Full text

[Back to Overview]  [IACM Homepage]